HighTide Therapeutics, Inc.

君圣泰医药

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2511)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

The board (the "**Board**") of directors (the "**Director(s)**") of HighTide Therapeutics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce the audited consolidated annual results of the Group for the year ended December 31, 2023 (the "**Reporting Period**"), together with the comparative figures for the year ended December 31, 2022. These annual results have been reviewed by the audit committee of the Board (the "**Audit Committee**").

In this announcement, "we", "us" and "our" refer to the Company and where the context otherwise requires, the Group. Certain amount and percentage figure included in this announcement have been subject to rounding adjustments or have been rounded to one or two decimal places, as appropriate. Any discrepancies in any table, chart or elsewhere totals and sums of amounts listed therein are due to rounding.

FINANCIAL HIGHLIGHTS

	Year ended December 31, 2023 *RMB'000*	Year ended December 31, 2022 *RMB'000*	Year-on-year change *%*
Loss before tax	**(939,230)**	(190,205)	393.8
Loss for the year	**(939,306)**	(190,237)	393.8
Adjusted net loss for the year*	**(288,443)**	(183,807)	56.9

* Adjusted net loss for the year is not defined under the International Financial Reporting Standard (the "**IFRS**"), it represents the loss for the year excluding the effect brought by fair value changes on convertible redeemable preferred shares, expenses under the employee long-term incentive plans and listing expenses.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

Year ended 31 December 2023

	Notes	**2023** ***RMB'000***	2022 *RMB'000*
Other income and gains	4	**34,214**	20,581
Fair value (losses)/gains on convertible redeemable preferred shares		**(522,160)**	23,242
Other expenses		**(2,647)**	(7,518)
Research and development costs		**(311,567)**	(182,651)
Administrative expenses		**(136,670)**	(43,433)
Finance costs	5	**(400)**	(426)
LOSS BEFORE TAX		**(939,230)**	(190,205)
Income tax expenses	6	**(76)**	(32)
LOSS FOR THE YEAR		**(939,306)**	(190,237)
Attributable to:			
Owners of the parent		**(939,306)**	(190,237)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT			
Basic and diluted			
For loss for the year *(RMB per share)*	8	**(3.62)**	(0.75)

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

Year ended 31 December 2023

	2023	2022
	RMB'000	*RMB'000*
LOSS FOR THE YEAR	**(939,306)**	(190,237)
OTHER COMPREHENSIVE LOSS		
Other comprehensive loss that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of the financial statements of subsidiaries	**(2,031)**	(20,342)
Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of the financial statements of the Company	**(11,411)**	(13,309)
OTHER COMPREHENSIVE LOSS FOR THE YEAR, NET OF TAX	**(13,442)**	(33,651)
TOTAL COMPREHENSIVE LOSS FOR THE YEAR	**(952,748)**	(223,888)
Attributable to:		
Owners of the parent	**(952,748)**	(223,888)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 December 2023

	Notes	2023 *RMB'000*	2022 *RMB'000*
NON-CURRENT ASSETS			
Property, plant and equipment		**2,410**	2,153
Right-of-use assets		**12,571**	2,653
Other non-current assets		**1,302**	–
Total non-current assets		**16,283**	4,806
CURRENT ASSETS			
Prepayments, other receivables and other assets		**43,052**	10,821
Financial assets at fair value through profit or loss ("FVTPL")		**127,489**	–
Short-term time deposits		**–**	427,857
Cash and bank balances		**608,212**	412,340
Total current assets		**778,753**	851,018
CURRENT LIABILITIES			
Trade payables	9	**30,507**	21,699
Other payables and accruals		**43,336**	28,747
Interest-bearing bank borrowings		**3,500**	8,150
Lease liabilities		**2,468**	1,111
Convertible redeemable preferred shares		**–**	1,260,013
Total current liabilities		**79,811**	1,319,720
NET CURRENT ASSETS/(LIABILITIES)		**698,942**	(468,702)
TOTAL ASSETS LESS CURRENT LIABILITIES		**715,225**	(463,896)
NON-CURRENT LIABILITIES			
Lease liabilities		**10,464**	1,513
Deferred income		**1,987**	5,119
Total non-current liabilities		**12,451**	6,632
Net assets/(liabilities)		**702,774**	(470,528)
EQUITY			
Equity attributable to owners of the parent			
Share capital		**364**	36
Treasury shares		**(44)**	(6)
Reserves/(deficits)		**702,454**	(470,558)
Total equity/(deficits)		**702,774**	(470,528)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. CORPORATE AND GROUP INFORMATION

HighTide Therapeutics, Inc. was established in the Cayman Islands on 28 February 2018 by Great Mantra Group Limited and its registered address is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands.

The Company is an investment holding company. During the year, the Company and its subsidiaries (collectively referred to as the "**Group**") are involved in the research and development of pharmaceutical products.

The Company was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on 22 December 2023 ("**Listing Date**").

2.1 BASIS OF PREPARATION

These financial statements have been prepared in accordance with International Financial Reporting Standards ("**IFRSs**"), which include all standards and interpretations approved by the International Accounting Standards Board ("**IASB**") and the disclosure requirements of the Hong Kong Companies Ordinance. They have been prepared under the historical cost convention, except for unlisted fund investments which have been measured at fair value. These financial statements are presented in Renminbi (RMB) and all values are rounded to the nearest thousand (RMB'000) except when otherwise indicated.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The Group has adopted the following new and revised IFRSs for the first time for the current year's financial statements.

IFRS 17	Insurance Contracts
Amendments to IAS 1 and IFRS Practice Statement 2	Disclosure of Accounting Policies
Amendments to IAS 8	Definition of Accounting Estimates
Amendments to IAS 12	Deferred Tax related to Assets and Liabilities arising from a Single Transaction
Amendments to IAS 12	International Tax Reform – Pillar Two Model Rules

2.3 ISSUED BUT NOT YET EFFECTIVE IFRSs

The Group has not applied the following revised IFRSs, that have been issued but are not yet effective, in these financial statements. The Group intends to apply these revised IFRSs, if applicable, when they become effective.

Amendments to IFRS 10 and IAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture[3]
Amendments to IFRS 16	Lease Liability in a Sale and Leaseback[1]
Amendments to IAS 1	Classification of Liabilities as Current or Non-current[1]
Amendments to IAS 1	Non-current Liabilities with Covenants[1]
Amendments to IAS 7 and IFRS 7	Supplier Finance Arrangements[1]
Amendments to IAS 21	Lack of Exchangeability[2]

[1] Effective for annual periods beginning on or after 1 January 2024

[2] Effective for annual periods beginning on or after 1 January 2025

[3] No mandatory effective date yet determined but available for adoption

The Group is in the process of making an assessment of the impact of these revised IFRSs upon initial application. So far, the Group considers that these revised IFRSs may result in changes in accounting policies and are unlikely to have a significant impact on the Group's results of operations and financial position.

3. OPERATING SEGMENT INFORMATION

The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment in a manner consistent with the way in which information is reported internally to the Group's senior management for purposes of resource allocation and performance assessment. Therefore, no further operating segment analysis thereof is presented.

Geographical information

During the reporting period, since almost all of the Group's non-current assets were located in Chinese Mainland, no geographical segment information in accordance with IFRS 8 *Operating Segments* is presented.

Information about major customers

No revenue was derived during the year. Therefore, no information about major customers is presented.

4. OTHER INCOME AND GAINS

An analysis of other income and gains is as follows:

	2023	2022
	RMB'000	*RMB'000*
Other income and gains		
Government grants related to expense items*	**9,769**	7,828
Government grants related to assets**	**132**	186
Bank interest income	**1,854**	3,545
Investment income from short-term time deposits	**22,245**	7,822
Other investment income from financial assets at FVTPL	**181**	1,012
Others	**33**	188
Total other income and gains	**34,214**	20,581

* Government grants related to expense items mainly represent subsidies received from local governments for the purpose of compensation of expenses for research and clinical trial activities, allowance for new drug development and talent funds. The main grantor is the Development and Reform Commission of Shenzhen Municipality. Government grants received for which related expenses have not yet been incurred are included in deferred income in the statement of financial position.

** Grants related to assets are credited to deferred income and released to the consolidated statement of profit or loss in equal annual instalments over the estimated useful lives of the related assets.

5. FINANCE COSTS

An analysis of finance costs is as follows:

	2023	2022
	RMB'000	*RMB'000*
Interest on interest-bearing bank borrowings	**262**	303
Interest on lease liabilities	**138**	123
Total	**400**	426

6. INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Cayman Islands

Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gains. In addition, upon payments of dividends by the Company to its shareholders, no Cayman Islands withholding tax is imposed.

British Virgin Islands

Under the current laws of the British Virgin Islands ("**BVI**"), the subsidiary incorporated in the BVI is not subject to tax on income or capital gains. In addition, upon payments of dividends by these subsidiaries to their shareholders, no BVI withholding tax is imposed.

Hong Kong

The subsidiary incorporated in Hong Kong is subject to income tax at the rate of 8.25% (2022: 8.25%) on the estimated assessable profits arising in Hong Kong during the year.

Chinese Mainland

No provision for Chinese Mainland income tax pursuant to the Corporate Income Tax Law of the PRC and the respective regulations (the "**CIT Law**") has been made as the Group's subsidiaries which operate in Chinese Mainland are in loss position and have no estimated taxable profits.

Shenzhen HighTide was approved as a high technology enterprise under the relevant tax rules and regulations in December 2019, and accordingly, is entitled to a reduced preferential CIT rate of 15% from 2019 to 2021. This qualification is subject to review by the relevant tax authority in the PRC for every three years. The renewed qualification was obtained in December 2022 and Shenzhen HighTide is entitled a preferential income tax rate of 15% from 2022 to 2024.

JSK Consumer Healthcare Ltd, Hebei Puhui Pharmaceutical Co., Ltd., Shanghai HighTide Biopharmaceutical Ltd., Shanghai Fusion Therapeutics Inc. and Nanchang Fusion Therapeutics Inc. have met the requirement under the relevant tax rules and regulations for small and low-profit enterprises, and accordingly, are subject to a reduced preferential CIT at a rate of 20%, and the portion of the annual taxable income not more than RMB1,000,000 is entitled to be included in the actual taxable income at reduced rates of 12.5% in 2022 and 25% in 2023, while the portion of the annual taxable income exceeding RMB1,000,000 but not exceeding RMB3,000,000 is entitled to be included in the actual taxable income at reduced rates of 25% in 2022 and 2023.

Australia

The subsidiary incorporated in Australia is subject to income tax at the rate of 25% (2022: 25%) on the estimated assessable profits arising in Australia during the year.

USA

The subsidiary incorporated in Maryland, the USA is subject to statutory United States federal corporate income tax at a rate of 21% (2022: 21%). In addition, it is also subject to the state income tax in Maryland at a rate of 8.25% (2022: 8.25%) during the year. Other states including California, Florida, and New Jersey also impose state income tax on the subsidiary to the extent that a sufficient nexus, or taxable connection, exists between the subsidiary and the respective states. The subsidiary was subject to the state income tax in California at a rate of 8.84% (2022: 8.84%), in Florida at a rate of 5.50% (2022: 5.50%), and in New Jersey at a rate of 7.50% (2022: 7.50%) during the year.

A reconciliation of the tax expense applicable to loss before tax at the statutory tax rates for the jurisdictions in which the Company and the majority of its subsidiaries are domiciled to the tax expense at the effective tax rates, is as follows:

	2023	2022
	RMB'000	*RMB'000*
Loss before tax	**(939,230)**	(190,205)
Tax at the applicable tax rate (25%)	**(234,808)**	(47,551)
Different tax rates enacted by local authorities	**185,955**	23,233
Additional deductible allowance for qualified research and development costs	**(14,837)**	(12,287)
Income not subject to tax	**(15)**	(12)
Expenses not deductible for tax	**8,202**	619
Deductible temporary differences and tax losses not recognised	**55,579**	36,030
Tax charge at the Group's effective rates	**76**	32

7. DIVIDENDS

No dividend was paid or declared by the Company during the year (2022: Nil).

8. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic loss per share amount is based on the loss for the year attributable to ordinary equity holders of the parent and the weighted average number of ordinary shares of 259,688,923 (2022: 254,825,232) in issue (excluding shares reserved for share incentive scheme) during the year.

In the calculation of the weighted average number of ordinary shares outstanding for the years ended 31 December 2023 and 2022, the shares issued to existing shareholders before public offering through the Capitalisation Issue had been adjusted retrospectively as if those shares have been issued since 1 January 2022.

No adjustment was made to the basic loss per share amounts presented for the years ended 31 December 2023 and 2022 in respect of a dilution as the impact of the convertible redeemable preferred shares and share-based payment had an anti-dilutive effect on the basic loss per share amounts presented.

Loss per share (basic and diluted) (RMB per share)for this year is (3.62)(2022: (0.75)).

9. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	2023	2022
	RMB'000	*RMB'000*
Within one year	**30,507**	21,699

The trade payables are non-interest-bearing and are normally settled within one month after the receipt of the invoice.

OVERVIEW

We are a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. We have developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which five are at clinical-stage. Our HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. Our other product candidates include HTD4010, HTD1804, HTD1805 and HTD2802.

We are dedicated to developing multifunctional and multi-target therapies that treat complex metabolic and digestive diseases with a systemic approach, providing effective and safe options to improve overall clinical benefits of patients. As an integrated company with operations in the United States, Mainland China, Hong Kong and Australia, our global presence, experience and knowledge allow us to conduct high-quality multi-center clinical trials in a cost-effective and time-efficient manner. With our accumulated extensive successful experience in building and developing a broad pipeline of innovative therapies for metabolic and digestive diseases, we expect to provide the market with a steady roll-out of competitive products that aim to address unmet clinical needs in complex metabolic and digestive diseases.

OUR PRODUCTS AND PRODUCT PIPELINE

As of the date of this announcement, we have researched and developed in-house a pipeline with five proprietary drug candidates covering nine indications, including five indications that are at clinical stage. The following chart summarizes the development status of our drug candidates as of the date of this announcement:



Abbreviations: *MASH: metabolic dysfunction-associated steatohepatitis (formerly known as nonalcoholic steatohepatitis or "**NASH**") ("**MASH**"); T2DM: type 2 diabetes mellitus ("**T2DM**"); PSC: primary sclerosing cholangitis ("**PSC**"); PBC: primary biliary cholangitis ("**PBC**"); SHTG: severe hypertriglyceridemia ("**SHTG**"); AH: alcoholic hepatitis ("**AH**"); IBD: inflammatory bowel disease ("**IBD**"); FTD: Fast Track Designation ("**FTD**"); ODD: Orphan Drug Designation ("**ODD**"); Ph: Phase.*

Notes:

1. Researched and developed in-house. We have granted Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (深圳市海普瑞藥業集團股份有限公司) ("**Hepalink**") an exclusive, sublicensable (solely to Hepalink's designated wholly-owned subsidiaries), non-transferable license for the commercialization of HTD1801 for NASH and PSC in Europe. The Company reserved the rights to (i) research, develop and manufacturing HTD1801 globally; (ii) commercialize HTD1801 for any indications outside Europe; (iii) commercialize HTD1801 in Europe for any indications other than NASH and PSC; and (iv) import and export HTD1801.

2. We have completed a Phase Ib/IIa trial for hypercholesterolemia in Australia and a Phase IIa trial for MASH in the United States. Based on the United States Food and Drug Administration's ("**FDA**") written responses to the pre-investigational new drug meeting, the FDA concluded that the available preclinical and clinical data of the above trials was adequate to support the initiation of Phase II trial for SHTG.

HTD1801

- Our core product, HTD1801, a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. It is a pivotal-stage, self-developed, multifunctional, multi-target, "pipeline-in-a-product" drug candidate. It is being developed for multiple metabolic and digestive indications, including MASH, T2DM, PSC, PBC and SHTG.

MASH

- In March 2024, resmetirom, a thyroid hormone receptor β-selective agonist, became the first drug receiving marketing approval from the FDA for the treatment of MASH patients with moderate to advanced liver fibrosis. Given the disease's pathogenetic complexity and heterogeneity, the treatment of MASH is trending toward a multifunctional therapeutic approach.

- We have completed a randomized, double-blind Phase I study of HTD1801 in healthy subjects in Australia and a randomized, double-blind, placebo-controlled Phase IIa study of HTD1801 in patients with MASH and T2DM in the United States in March 2020. The Phase IIa study met the primary endpoint, which showed that HTD1801 resulted in statistically significant, meaningful improvements in liver fat content, as assessed by MRI-PDFF, compared to a placebo.

- We presented data from the Phase IIa study of HTD1801 on improvements in liver fibroinflammation in patients with MASH and T2DM at the European Association for the Study of the Liver (EASL) Congress 2023 held in June 2023, and The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD) held in November 2023.

- We are currently conducting a Phase IIb study of HTD1801 for the treatment of MASH with T2DM or pre-diabetes. The study has initiated in the United States, Hong Kong and Mainland China.

- The patient enrollment of Phase IIb will be completed by March 31, 2024. We currently plan to complete the clinical trial and conduct data readout in the first half of 2025.

T2DM

- T2DM and metabolic dysfunction-associated steatotic liver disease ("**MASLD**", formerly known as nonalcoholic fatty liver disease) are intricately and bi-directionally associated, where T2DM aggravates MASLD into more severe forms of liver disorders, such as MASH, cirrhosis and hepatocellular carcinoma, while the presence of MASLD increases the incidence and severity of T2DM and makes T2DM patients more susceptible to comorbidities such as cardiovascular diseases ("**CVDs**").

- We completed a Phase I study in healthy subjects in Mainland China in November 2021 and a Phase Ib study in Chinese subjects with T2DM in September 2022. We further completed a Phase II study in Chinese subjects with T2DM in January 2023.

- Our completed Phase Ib and Phase II clinical trials in China have demonstrated a strong therapeutic effect in improving glucose metabolism, including statistically significant decreases in HbA1c and fasting glucose levels, which may be the result of decreased insulin resistance based on observed reductions in HOMA-IR with HTD1801. Collective results from our Phase Ib T2DM trial, Phase II T2DM trial and Phase IIa MASH and T2DM trial suggest that HTD1801 has broad efficacy on glucose homeostasis, other cardiometabolic markers and liver health, supporting a differentiated profile compared to other anti-diabetic agents.

- We presented data from Phase II study on improvements in glycemic control with HTD1801 in patients with T2DM at the 59th Annual Meeting of the European Association for the Study of the Diabetes (EASD) held in October 2023.

- We initiated Phase III registrational trials of HTD1801 for the treatment of T2DM in China in November 2023. Based on the comprehensive benefits observed for HTD1801 treatment, coupled with its safety profile and ease of administration, we believe that HTD1801 has the potential to become a therapy for T2DM patients who also suffer from metabolic comorbidities such as MASLD and dyslipidemia.

- The patient enrollment of the Phase III registration trials of HTD1801 will be completed in 2024, and we currently plan to complete the clinical trial and conduct data readout in 2025.

PSC

- PSC is a rare, chronic cholestatic liver disease characterized by intrahepatic and extrahepatic bile duct injury. Inflammation and fibrosis of the bile ducts lead to structural damage, impaired bile flow and progressive liver dysfunction. PSC has been identified by the European Association for the Study of the Liver as one of the largest unmet clinical needs in the category of liver disease. HTD1801 is precisely engineered to target the disease's complex pathogenic mechanisms through a multifunctional synergistic approach.

- HTD1801 provides a unique and comprehensive treatment of the gut-liver-biliary system, acting through multiple mechanisms to address the complex pathogenesis of PSC, including a choleretic effect achieved by displacing toxic bile acids from the bile acid pool and a variety of anti-inflammatory effects. In addition, HTD1801 treatment has demonstrated positive changes in the gut microbiome, an important contributor to the pathogenesis of PSC.

- We completed a Phase II clinical trial of HTD1801 for PSC in the United States and Canada in August 2020, with the HTD1801 treatment group demonstrating a statistically significant reduction in serum alkaline phosphatase, a key biomarker indicating the presence of cholestatic liver disease, compared to the placebo group. HTD1801 treatment was also associated with improvements in markers of liver injury and inflammation. In addition to its efficacy profile, HTD1801 demonstrated a good safety profile in this patient population including liver-related safety. HTD1801 has been granted FTD and ODD from FDA for the treatment of PSC, which allows for expedited regulatory review.

PBC

- PBC is a rare and serious liver disease resulting from a slow, progressive destruction of the intra-hepatic small bile ducts. There are two approved treatments for PBC to date, while each with its own limitations. Thus, there remains an unmet medical needs in patients with PBC.

- We completed Phase II open-label study in the United States in May 2022, which demonstrated proof of concept of HTD1801 for the treatment of PBC patients with an incomplete response to ursodeoxycholic acid (UDCA) treatment. Upon transition from UDCA to HTD1801, efficacy across multiple endpoints was observed with HTD1801 therapy, including a reduction in alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT), markers of cholestatic injury, as well as a reduction in total bilirubin levels, indicative of improved liver function. Our Phase II clinical results suggest that additional benefits are obtained with HTD1801 monotherapy over UDCA alone, potentially in part driven by the BBR moiety of HTD1801 and the improved physicochemical characteristics of HTD1801.

- In addition to the efficacy profile, HTD1801 demonstrated a good safety profile in this patient population including liver-related safety. In particular, pruritus, a common symptom of PBC, showed improvement with HTD1801 treatment.

SHTG

- SHTG is the presence of high levels of triglycerides, a type of fat, in the blood. SHTG is well known to be associated with other complex and serious disorders such as acute pancreatitis and CVDs. Existing pharmacological interventions primarily include the use of fibrates, omega-3 fatty acids, statins and niacin, but these treatment options either have limited efficacy or are associated with safety concerns. It is clear that there remains a medical need for safe and effective therapies for the treatment of adult patients with SHTG, therapies that address not only triglycerides levels but also comorbid conditions.

- For SHTG, preclinical studies demonstrated that HTD1801 could improve lipids in hamster models of dyslipidemia and MASLD. In addition, in a pooled analysis of clinical studies of MASH and hypercholesterolemia, focusing on subjects with baseline TGs above 200 mg/dL (hypertriglyceridemia), treatment with HTD1801 was associated with clinically meaningful reductions in TG levels, which supports the therapeutic potential of HTD1801 in SHTG.

- We have completed Phase I clinical trial in healthy subjects in Australia. We will continue to evaluate the clinical progress of HTD1801 and, taking into account the overall strategy and resources allocation of the Group, assess the timeframe of initiating the Phase II clinical trial of HTD1801 for the treatment of SHTG.

HTD4010

- Building on our expertise in the development of HTD1801, we have also invested in and developed our pipeline to cover AH, obesity, IBD and other metabolic diseases to address large unmet medical needs of other patient populations. For the treatment of AH, we are advancing the early clinical development of HTD4010. AH is one of the manifestations from alcohol-associated liver disease characterized by acute liver inflammation.

- Our HTD4010 is a Phase I clinical-stage, polypeptide drug for the treatment of complex, life-threatening diseases such as AH, which is caused by chronic heavy alcohol abuse or a sudden, drastic increase in alcohol consumption. It is characterized by severe inflammation and, ultimately, liver failure and death. HTD4010 is a Toll-like receptor 4 inhibitor potentially capable of modulating the innate immune response and the resulting liver inflammation, a major contributor to AH pathogenesis.

HTD1804

- An additional drug candidate, HTD1804, is under evaluation for the treatment of obesity, which is a growing global health risk associated with a wide range of comorbidities, most notably CVDs and T2DM.

- Our HTD1804 is a preclinical-stage, small molecule multifunctional therapy for the treatment of obesity, a growing global health risk associated with a wide range of comorbidities, most notably CVDs and T2DM. Preclinical studies have shown that HTD1804 may be an important modulator of energy metabolism to provide cardiovascular protection, and can effectively reduce the body weight of animals with obesity as well as lipid- and glucose-lowering effects.

HTD1805

- HTD1805, another drug candidate in our pipeline, is a multifunctional small molecule drug for the treatment of metabolic diseases. It is a preclinical-stage, multifunctional small molecule drug for the treatment of metabolic diseases. HTD1805 is prepared with the similar design rational as HTD1801, and the efficacy and safety profiles of the active moieties forming demonstrate the potential of HTD1805 in treating various metabolic diseases.

HTD2802

- Our HTD2802 is a preclinical-stage, multifunctional drug for the treatment of IBD, a common GI tract disorder. The existing IBD drugs fail to adequately control the symptoms and complications in many patients. In preclinical studies, HTD2802 has shown positive effects on improving stool formation, relieving abnormal weight loss and reducing the occurrence of fecal occult blood, as well as reducing inflammatory cytokine levels and preventing pathological injury.

Looking forward, we will continue to advance our pipeline of drug candidates through clinical development and continue to seek to expand indication coverage of our pipeline. With respect to commercialization, based on the expected approval timeline of each indication of HTD1801 in our pipeline, we expect to file new drug application with the NMPA for HTD1801 for T2DM in 2025. In anticipation of the upcoming milestone, we are actively seeking domestic partners with a strong commercialization network and expertise in T2DM. Subject to our global clinical development plan, we also plan to commercialize HTD1801 for MASH, PSC, PBC and SHTG in multiple jurisdictions, including but not limited to the United States, European Union and China.

THERE IS NO ASSURANCE THAT WE WILL BE ABLE TO ULTIMATELY DEVELOP AND MARKET ANY OF OUR PIPELINE PRODUCTS SUCCESSFULLY.

RESEARCH AND DEVELOPMENT CAPABILITY

We believe that our continued research and development ("**R&D**") is the key driver of our business growth and competitiveness.

R&D Team

Our R&D team has strong expertise, deep understanding, and broad development experience in metabolic and digestive diseases. Our R&D team is generally responsible for the global development of our pipeline products. For our internally discovered and developed drug candidates, we conducted drug discovery, quality assurance and clinical activities including: (i) coordinating all clinical development activities; (ii) designing the key aspects of the clinical studies; (iii) designing and coordinating the selection process for qualified contract research organizations ("**CROs**") to assist in engaging clinical sites and coordinating clinical studies once commenced; (iv) supervising the clinical studies; and (v) overseeing extensive regulatory outreach and coordination in China and other jurisdictions. Our R&D team is led by a team of world-class scientists with years of drug development experience. As of December 31, 2023, our core R&D personnel consisted of 11 members covering the fields of chemistry, biology, pharmacology and medicine.

Drug Discovery

We have worked on our product candidates' advancement for more than 10 years and developed product candidates in-house. Our drug discovery team members have expertise in biology, medicinal chemistry, drug metabolism and pharmacokinetics, chemistry and early clinical areas, which support our product development.

Clinical Development

As of December 31, 2023, the clinical development team consisted of 30 members, including scientists and physicians with strong drug development experience, who participate in clinical development strategy development, clinical trial protocol design, clinical trial operation organization, drug safety monitoring, and clinical trial quality control. Our clinical development staff represent a highly skilled and experienced team of professionals who work collaboratively to design and execute complex clinical trials and drug development programs. Our core capabilities in the area of development include clinical trial design, regulatory and quality compliance, project management, clinical operations, medical writing, safety monitoring and drug development strategy. Our team has the expertise to design clinical trials that are rigorous and compliant with regulatory requirements. This involves collaborating internally, with experts and regulatory authorities to determine the appropriate patient population, defining endpoints, and selecting appropriate control groups. The clinical development unit of our Company manages all stages of clinical trials, including protocol design and oversees, operations/conduct, and the collection and analysis of clinical data.

FINANCIAL OVERVIEW

The following discussion is based on, and should be read in conjunction with, the financial information and notes included elsewhere in this announcement.

Other Income and Gains

Our other income and gains increased by RMB13.6 million from RMB20.6 million for the year ended December 31, 2022 to RMB34.2 million for the year ended December 31, 2023, representing an increase of 66.2%.

The increase in the other income and gains was primarily because of the increase of approximately RMB14.4 million in investment income from short-term time deposits.

Fair Value (Losses)/Gains on Convertible Redeemable Preferred Shares

Our fair value changes of convertible redeemable preferred shares decreased from a gain of RMB23.2 million for the year ended December 31, 2022 to a loss of RMB522.2 million for the year ended December 31, 2023, as the fair value of the convertible redeemable preferred shares was deemed to be increased upon the completion of the listing (the "**Listing**") of the ordinary shares of the Company (the "**Share(s)**") on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on December 22, 2023 (the "**Listing Date**"). Such loss on the fair value changes of convertible redeemable preferred shares was non-cash and non-recurring, as all of the Company's preferred shares were converted to ordinary shares upon the Listing Date. The Group will not incur any additional losses relating to the fair value changes of preferred shares going forward.

Other Expenses

Our other expenses decreased from RMB7.5 million for the year ended December 31, 2022 to RMB2.6 million for the year ended December 31, 2023, a decrease of 64.8%, which was primarily attributable to fluctuations in foreign currency exchange rates and currency translation.

Research and Development Costs

Our research and development costs primarily consist of (i) third-party contracting expenses primarily including early stage discovery expenses, preclinical expenses, and clinical development expenses for our drug candidates; (ii) staff costs, primarily consisting of salaries and benefits for our R&D team; (iii) expenses under the employee long-term incentive plans, representing expenses associated with share options granted to our R&D team; and (iv) others, primarily including rental, depreciation and amortization in relation to fixed assets, intangible assets, right-of-use assets and raw materials.

Our research and development costs increased by 70.6% from RMB182.7 million for the year ended December 31, 2022 to RMB311.6 million for the year ended December 31, 2023. The increase was mainly attributable to an increase of approximately RMB79.9 million in third-party contracting expenses and an increase of approximately RMB39.3 million in the expenses under the employee long-term incentive plans.

The following table sets forth a breakdown of our research and development costs for the years indicated:

	Year ended December 31,			
	2023		2022	
	RMB'000	***%***	*RMB'000*	*%*
Third-party contracting expenses	**203,258**	**65**	123,377	68
Staff costs	**39,288**	**13**	35,148	19
Expenses under the employee long-term incentive plans	**59,711**	**19**	20,406	11
Others	**9,310**	**3**	3,720	2
Total	**311,567**	**100**	182,651	100

Administrative Expenses

Our administrative expenses increased by 214.7% from RMB43.4 million for the year ended December 31, 2022 to RMB136.7 million for the year ended December 31, 2023. The increase in administrative expenses was primarily attributable to the increase in professional service fees in connection with the Listing, and the increase in expenses under the employee long-term incentive plans and staff costs.

Finance Costs

Our finance costs were RMB400,000 for the year ended December 31, 2023, as compared to RMB426,000 for the year ended December 31, 2022. Our finance costs primarily consist of interest on interest-bearing bank borrowings and lease liabilities. The decrease in finance costs was primarily attributable to the decrease in interest on interest-bearing bank borrowings.

Loss for the Year

As a result of the above, we recorded a loss of RMB939.3 million for the year ended December 31, 2023, as compared to RMB190.2 million for the year ended December 31, 2022.

Capital Management

The primary objectives of the Group's capital management are to safeguard the Group's ability to continue as a going concern and to maintain healthy capital ratios in order to support its business and maximize value to the holders of the Shares (the "**Shareholders**").

The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Group may return capital to the Shareholders or issue new Shares. The Group is not subject to any externally imposed capital requirements. No changes were made in the objectives, policies or processes for managing capital during the year ended December 31, 2023.

Liquidity and Capital Resources

The Group has always adopted a prudent treasury management policy. The Group places strong emphasis on having funds readily available and accessible and is in a stable liquidity position with sufficient funds in standby banking facilities to cope with daily operations and meet its future development demands for capital.

As of December 31, 2023, the current assets of the Group were RMB778.8 million, of which cash and bank balances amounted to RMB608.2 million and other current assets amounted to RMB170.6 million. The Group's cash and bank balances increased by 47.5% from RMB412.3 million as at December 31, 2022 to RMB608.2 million as at December 31, 2023. The increase was mainly due to the proceeds generated from the Listing. As at December 31, 2023, cash and bank balances were mainly denominated in Hong Kong dollars, United States dollars and Renminbi.

As of December 31, 2023, the current liabilities of the Group were RMB79.8 million, including trade payables of RMB30.5 million, other payables and accruals of RMB43.3 million, interest-bearing bank borrowings of RMB3.5 million and lease liabilities of RMB2.5 million.

Bank Borrowings

As of December 31, 2023, the Group had outstanding interest-bearing bank borrowings of approximately RMB3.5 million (December 31, 2022: RMB8.2 million) which were denominated in RMB and bearing interest on commercial bank borrowings at fixed annual interest rates ranging from 3.65% to 3.8%.

Charges on Group Assets

As of December 31, 2023, there were no charges on assets of the Company (2022: nil).

Key Financial Ratios

The following table sets forth the key financial ratios for the dates indicated:

	As at December 31,	
	2023	2022
Gearing Ratio [(1)]	**0.5%**	(2%)
Current Ratio [(2)]	**9.8**	0.6

Notes:

(1) Equals bank loans and other borrowings divided by total equity as of the same date.

(2) Equals current assets divided by current liabilities as of the same date.

Significant Investments

During the year ended December 31, 2023 and before the Listing Date, the Group made investments through two structured entities, Apollo Multi-Asset Growth Fund and Chaince Capital Fund LP (together the "**Funds**"), that the Group invested with initial capital contribution of US$12.5 million each. As at December 31, 2023, the underlying assets purchased by Apollo Multi-Asset Growth Fund and Chaince Capital Fund LP mainly included listed equity investments, which were classified as financial instruments at FVTPL of RMB42.5 million and RMB85 million (representing 5.3% and 10.7% of the Group's total assets as at December 31, 2023), respectively. The listed equity investments are non-principal guaranteed with floating return. Apollo Multi-Asset Growth Fund also made short-term time deposits within six months at banks of RMB41.0 million (representing 5.2% of the Group's total assets as at December 31, 2023). During the year ended December 31, 2023, the underlying assets purchased by the Funds generated an investment income of RMB0.3 million.

Save as disclosed above, the Group did not have any significant investments and did not have other plans for significant investments or capital assets as at the date of this announcement.

Material Acquisitions and Disposals

The Group did not have any material acquisitions or disposals of subsidiaries, associates and joint ventures for the year ended December 31, 2023.

Contingent Liabilities

The Group did not have any material contingent liabilities as at December 31, 2023.

Capital Expenditure and Commitments

Our capital expenditure for the year ended December 31, 2023 was RMB0.8 million, compared to RMB0.2 million for the year ended December 31, 2022. The increase was primarily attributable to purchases of machinery and equipment. Our capital expenditure primarily consisted of the purchase of (i) machinery and equipment, (ii) furniture, fittings and equipment and (iii) leasehold improvements.

As of December 31, 2023, we had the following contractual commitments:

	2023	2022
	RMB'000	*RMB'000*
Leasehold improvements	**2,645**	–
Total	**2,645**	–

We had a lease contract that had not yet commenced as at December 31, 2023. The future lease payments for this non-cancellable lease contract are RMB1.6 million due within one year and RMB11.7 million due in the second to fifth years.

Foreign Currency Risk

We have transactional currency exposures. Our Group's transactions were primarily denominated in US dollars, Renminbi and Hong Kong dollars. Certain of our cash and bank balances and trade and other payables are denominated in non-functional currency of the Company and exposed to foreign currency risk. We currently do not have a foreign currency hedging policy. However, our management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

Non-IFRS Measures

To supplement our consolidated statements of profit or loss which are presented in accordance with IFRS, we also use adjusted net loss as non-IFRS measures, which are not required by, or presented in accordance with, IFRS. We believe that the presentation of non-IFRS measures when shown in conjunction with the corresponding IFRS measures provides useful information to investors and management in facilitating a comparison of our operating performance from year to year by eliminating potential impacts of certain non-operational or one-off expenses that do not affect our ongoing operating performance, including changes in fair value of convertible redeemable preferred shares, expenses under the employee long-term incentive plans and listing expenses. Such non-IFRS measures allow investors to consider metrics used by our management in evaluating our performance. Changes in fair value of convertible redeemable preferred shares represent the changes in fair value of various rights associated with the preferred shares, which is non-recurring and non-operational in nature. Expenses under the employee long-term incentive plans are non-operational expenses arising from granting options to selected directors, employees and consultants of the Company, the amount of which may not directly correlate with the underlying performance of our business operations, and is also affected by non-operating performance related factors that are not closely or directly related to our business activities. With respect to share awards, determining its fair value involves a high-degree of judgment. Historical occurrence of expenses under the employee long-term incentive plans is not indicative of any future occurrence. Listing expenses are one-off expenses in relation to the Listing. Therefore, we do not consider changes in fair value of convertible redeemable preferred shares, expenses under the employee long-term incentive plans and Listing expenses to be indicative of our ongoing core operating performance and exclude them in reviewing our financial results. From time to time in the future, there may be other items that we may exclude in reviewing our financial results.

The use of the non-IFRS measures has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for or superior to analysis of, our results of operations or financial condition as reported under IFRS. In addition, the non-IFRS financial measures may be defined differently from similar terms used by other companies and therefore may not be comparable to similar measures presented by other companies.

The following table shows reconciliation of net loss for the year to our adjusted net loss for the years indicated:

	2023	2022
	RMB'000	*RMB'000*
Net loss for the year	**(939,306)**	(190,237)
Added:		
Fair value changes on convertible redeemable preferred shares	**522,160**	(23,242)
Expenses under the employee long-term incentive plans	**93,493**	25,621
Listing expenses	**35,210**	4,051
Adjusted net loss	**(288,443)**	(183,807)

Employees and Remuneration Policy

As at December 31, 2023, we had 66 employees in total. The following table sets forth the number of our employees categorized by function as of December 31, 2022 and December 31, 2023.

	Number of employees as at December 31, 2023	Number of employees as at December 31, 2022
Discovery and Clinical Development	**34**	31
CMC	**6**	4
Regulatory Affairs	**5**	7
Management Operations	**21**	27
Total	**66**	69

The total employee benefit expense (excluding Directors' and chief executive's remuneration) incurred by the Group was RMB116.3 million for the year ended December 31, 2023 (2022: RMB56.0 million). The increase in remuneration cost was primarily attributable to recruitment of more R&D personnel and the adoption of a new employee long-term incentive plan in 2023.

Our employees' remuneration comprises salaries, bonuses, provident funds, social security contributions, and other welfare payments. We have made contributions to our employees' social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds pursuant to applicable laws and regulations.

To maintain our workforce's quality, knowledge, and skill levels, we provide continuing education and training programs, including internal training, to improve their technical, professional or management skills. We also provide training programs to our employees from time to time to ensure their awareness and compliance with our policies and procedures in various aspects. Furthermore, we provide various incentives and benefits to our employees, including competitive salaries, bonuses and share-based payment, particularly our key employees.

The Company has adopted share incentive plans on January 22, 2020 and May 24, 2023, respectively. For further details, please refer to the paragraph headed "D. Incentive Plans" in Appendix IV to the prospectus of the Company dated December 14, 2023 (the "**Prospectus**").

OTHER INFORMATION

Compliance with the Corporate Governance Code

The Company recognizes the importance of good corporate governance for enhancing the management of the Company as well as preserving the interests of the Shareholders as a whole. The Company has adopted the Corporate Governance Code (the "**Corporate Governance Code**") contained in Appendix C1 to the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**") as its own code of corporate governance. The Directors are of the view that from the Listing Date to the date of this announcement, the Company has complied with all applicable code provisions of the Corporate Governance Code save and except for the following deviation from code provision C.2.1 of the Corporate Governance Code.

Under code provision C.2.1 of the Corporate Governance Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Dr. Liu Liping ("**Dr. Liu**") has being serving as the chairwoman of the Board since the Listing and Chief Executive Officer since February 2018. With extensive experience in the pharmaceutical industry and having served in our Company since its establishment, Dr. Liu is in charge of overall strategic planning, business direction and operational management of our Group. Our Board considers that vesting the roles of chairwoman and chief executive officer in the same person is beneficial to the management of our Group. The balance of power and authority is ensured by the operation of our Board and our senior management, which comprises experienced and diverse individuals. Our Board currently comprises two executive Directors, three non-executive Directors and three independent non-executive Directors, and therefore has a strong independence element in its composition.

The Board will continue to review the effectiveness of the corporate governance structure of the Group in order to assess whether separation of the roles of chairperson and the chief executive officer is necessary.

Compliance with the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code")

The Company has adopted the Model Code set out in Appendix C3 to the Listing Rules as its own code of conduct regarding dealings in the securities of the Company by the Directors and the Company's employees who, because of his/her office or employment, is likely to possess inside information in relation to the Company or its securities.

Upon specific enquiry, all Directors confirmed that they have complied with the Model Code during the period from the Listing Date to the date of this announcement. In addition, the Company is not aware of any non-compliance of the Model Code by the employees of the Company who are likely to be in possession of inside information of the Company during the period from the Listing Date to the date of this announcement.

Purchase, Sale or Redemption of the Company's Listed Securities

Neither the Company nor any of its subsidiaries purchased, redeemed or sold any of the Company's listed securities since the Listing Date to the date of this announcement.

Material Litigation

The Company was not involved in any material litigation or arbitration during the year ended December 31, 2023 which could have a material and adverse effect on our financial condition or results of operations. The Directors are also not aware of any material litigation or claims that are pending or threatened against the Company since the Listing Date and up to December 31, 2023 which could have a material and adverse effect on our financial condition or results of operations.

Use of Net Proceeds from the Listing

The total net proceeds from the issue of shares by the Company in its Listing amounted to approximately HK$194.1 million, after deducting the underwriting commission and other expenses payable by the Company in connection with the Listing. The balance of unutilized net proceeds amounted to approximately HK$194.1 million as at the end of the Reporting Period and the Company intends to use them in the same manner and proportions as described in the Prospectus and proposes to use the unutilized net proceeds in accordance with the expected timetable disclosed in the table below.

	Use of proceeds in the same manner and proportion as stated in the Prospectus *HK$ in million*	**Actual use of proceeds during the Reporting Period** *HK$ in million*	**Actual use of proceeds as at the end of the Reporting Period** *HK$ in million*	**Net proceeds unutilized as at the end of the Reporting Period** *HK$ in million*	**Expected timeframe for utilizing the remaining unutilized net proceeds**[*Note*]
Approximately 80.0% to fund the continuing clinical research and development activities of our HTD1801	155.2	–	–	155.2	December 2025
Approximately 5.0% to fund the ongoing research and development including R&D personnel costs and third party contracting expenses for HTD1804 for obesity	9.7	–	–	9.7	December 2025
Approximately 10.0% for the early drug discovery and development of other drug candidates from continuously upgrading and enhancing our FUSIONTX™ development approach	19.5	–	–	19.5	December 2025
Approximately 5.0% for working capital and other general corporate purposes	9.7	–	–	9.7	December 2025
Total	194.1	–	–	194.1	

Note: The expected timeframe for utilizing the remaining unutilized net proceeds is based on the best estimation of the factual business needs and future business development of the Group. It will be subject to change based on the current and future developments of market conditions and future business needs of the Group.

Audit Committee and Auditor

The Audit Committee has three members comprising three independent non-executive Directors, being Mr. TAN Bo (譚擘) (chairman of the Audit Committee with the appropriate professional qualifications), Dr. Jin LI (李靖) and Mr. HUNG Tak Wai (孔德偉), with terms of reference in compliance with the Listing Rules.

The Audit Committee has considered and reviewed the annual financial results for the year ended December 31, 2023, the accounting principles and practices adopted by the Company and the Group and discussed matters in relation to internal control, risk management and financial reporting with the management. There is no disagreement between the Board and the Audit Committee regarding the accounting treatment adopted by the Company. The Audit Committee considers that the annual financial results for the year ended December 31, 2023 are in compliance with the relevant accounting standards, rules and regulations and appropriate disclosures have been duly made. The Audit Committee has met with the independent auditor of the Company, Ernst & Young, and has also discussed matters with respect to the accounting policies and practices adopted by the Company and financial reporting matters.

The figures in respect of the Group's consolidated statement of financial position, consolidated statement of profit or loss and other comprehensive income and the related notes thereto for the year ended December 31, 2023 as set out in the preliminary announcement have been agreed by the Company's auditors to the amounts set out in the Group's draft consolidated financial statements for the year. The work performed by the Company's auditors in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently no assurance has been expressed by the Company's auditors on the preliminary announcement.

Events after the Reporting Period

As announced by the Company on January 19, 2024, the Group plans to expand its business presence to cover Hebei Province, China. Currently, the Group has offices and research and development centers in Shenzhen, Shanghai, Nanchang and Hong Kong. By expanding the business presence in Hebei Province, the Group aims to attract top-notch talents with strong academic background and industry experience in northern China for strengthening and diversifying the Group's industry and regulatory resources and/or raw materials supply capabilities. For details, please refer to the announcement of the Company dated January 19, 2024.

Mr. LI Li (李鋰) has resigned as a non-executive Director with effect from February 2, 2024, as he would like to devote more time to his personal engagement. For details, please refer to the announcement of the Company dated February 2, 2024.

Save as disclosed in this announcement, there were no important events affecting the Group occurred since December 31, 2023 and up to the date of this announcement.

Final Dividend

The Board did not recommend the distribution of a final dividend for the year ended December 31, 2023 (2022: nil).

Closure of Register of Members and Record Date

The register of members of the Company will be closed from Thursday, May 9, 2024 to Thursday, May 16, 2024, both days inclusive, in order to determine the identity of Shareholders who are entitled to attend and vote at the annual general meeting to be held on Thursday, May 16, 2024. In order to be eligible to attend and vote at the annual general meeting, all transfer accompanied by relevant share certificates and transfer forms must be lodged with the Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, Shops 1712–1716, 17th Floor Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong before 4:30 p.m. on Wednesday, May 8, 2024.

Publication of Annual Results Announcement and Annual Report

This announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.hightidetx.com). The annual report for the year ended December 31, 2023 containing all the information required by the Listing Rules will be dispatched to the Shareholders (if appropriate) in accordance with the Listing Rules and published on the websites of the Stock Exchange and the Company in due course.

By order of the Board
HighTide Therapeutics, Inc.
Dr. LIU Liping
Executive Director and Chief Executive Officer

Hong Kong, March 27, 2024

As at the date of this announcement, the Board comprises Dr. LIU Liping and Ms. YU Meng as executive Directors; Dr. ZHU Xun, Mr. MA Lixiong and Mr. JIANG Feng as non-executive Directors; and Mr. TAN Bo, Dr. Jin LI and Mr. HUNG Tak Wai as independent non-executive Directors.